NEO - MCAP CO - NeoGenomics, Inc.

NeoGenomics, Inc. (NEO) bases its business on genetic research and cancer diagnostics, generating revenue through clinical testing and pharmaceutical support. Reagent production capacities are fully utilized, and equipment modernization is proceeding without interruptions. The current metric stands at 2.48. The price action shown below reflects geopolitical logistics challenges regarding components and the protection of overseas patents.

The integration of ESG standards into waste disposal and data digitalization at NeoGenomics, Inc. (NEO) directly impacts the company's investment attractiveness and business resilience. By analyzing the total market capitalization of NeoGenomics, Inc. (NEO), investors assess the aggregate market value of all shares as an indicator of the issuer's margin of safety, allowing them to decouple speculative expectations from the business's actual capacity to withstand systemic risks and the threat of delisting.